The biotech's growth portfolio continues to add to its overall top line.

Biogen reported better-than-expected first-quarter earnings and revenue on Wednesday, and trimmed its full-year earnings outlook, citing charges related to business development activity.

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

Biogen first-quarter profit and revenue rose, buoyed by rising sales from its growth products, led by its drug to treat early ...

Prominent biotechnology company Biogen (BIIB) delivered a standout performance in the stock market on Wednesday. The company ...

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in ...

(RTTNews) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies. Through the ...

Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...

Biogen Inc. (NASDAQ: BIIB) stock climbed Monday as the company and TJ Biopharma announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s ...